hexastarch

HES200/0.62 is a second-generation, highly substituted hydroxyethyl starch (HES) solution used as an intravenous colloidal plasma volume expander. It is characterized by a mean molecular weight of 200 kDa and a molar degree of substitution of 0.62, which places it in the hexastarch category of HES products. Developed by Fresenius Kabi, it functions by increasing plasma oncotic pressure, thereby expanding intravascular volume and improving blood rheology in patients with hypovolemia or shock. Clinical research has also evaluated its impact on the systemic inflammatory response during major vascular surgeries, such as abdominal aortic aneurysm repair. Compared to newer, lower-substitution HES products (e.g., HES 130/0.4), HES 200/0.62 has a slower clearance rate and has been associated with a higher incidence of side effects, including impaired renal function and coagulopathy (iatrogenic von Willebrand syndrome).

Other names

hydroxyethyl starch 200/0.626% hydroxyethyl starch 200/0.62Pentafraction